Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial

Patrick N. A. Harris(University of Technology Sydney), David L. Paterson(The University of Queensland), Andrew J. Stewardson(Austin Health), Emma S. McBryde(The Royal Melbourne Hospital), Paul R. Ingram(Fiona Stanley Hospital), Jason A. Roberts(The University of Queensland), Benjamin A. Rogers(Monash University), Jonathan R. Iredell(Westmead Hospital), Jeffrey Lipman(Royal Brisbane and Women's Hospital), Sanjoy K. Paul(QIMR Berghofer Medical Research Institute), Eugene Athan(Deakin University), Anton Y. Peleg(Australian Regenerative Medicine Institute), Tiffany Harris‐Brown(The University of Queensland), Peter Baker(The University of Queensland), Spiros Miyakis(UNSW Sydney)
Trials
January 26, 2015
10.1186/s13063-014-0541-9
Cited by 73

Related Papers

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Antimicrobial Resistance in ESKAPE Pathogens
|Clinical Microbiology Reviews|2020|2k
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance
|JAMA|2018|761
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
|The Lancet Infectious Diseases|2017|521
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study
|Intensive Care Medicine|2012|449